Pleconaril, a new antiviral drug with activity against picoranvirus;Pleconaril, un nuevo farmaco antiviral con actividad frente a los picornavirus

Revista Espanola de Quimioterapia

Volumn 13, Issue 3, 2000, Pages 257-262

  Reina, J ^a   Ballesteros, F ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; INTERFERON; PLECONARIL; RIBAVIRIN; ANTIVIRUS AGENT; OXADIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; ENTEROVIRUS INFECTION; HUMAN; INTERFERON PRODUCTION; NONHUMAN; PHASE 3 CLINICAL TRIAL; PICORNAVIRUS; REVIEW; VIRUS RESISTANCE; ANIMAL; DRUG EFFECT; DRUG RESISTANCE; PICORNAVIRUS INFECTION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE; HUMANS; OXADIAZOLES; PICORNAVIRIDAE; PICORNAVIRIDAE INFECTIONS;

EID: 0033626408     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Picornaviridae: The viruses and their replication
2. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses and newer enteroviruses
3. Enteroviruses: Coxsackieviruses, echoviruses and polioviruses
4. Development of antiviral agents for picornavirus infections
5. Antiviral chemotherapy
6. Rapid development of drug resistant mutants of poliovirus
7. Guanidine-resistant mutants of aphthovirus induce the synthesis of an altered nonstractural polypeptide P34
8. Treatment of viral myocarditis with ribavirin in an animal preparation
9. Topical enviroxime against rhinovirus infection
10. Prophylaxis and therapy of virulent encephalomyocarditis virus in mice by monoclonal antibodies
11. Survival of athymic (nu/nu) mice after Theiler's routine encephalomyelitis virus infection by passive administration of neutralizing monoclonal antibody
12. Role of interferon, antibodies and macrophages in the protective effect of Corynebacterium parvum on encephalomyocarditis virus-induced disease in mice
13. Coxasackie B3 virus can replicate in cultured human fetal heart cells and is inhibited by interferon
14. Virus-specific, early appearing neutralizing activity and inteferon production in patients with acute hemorrhagic conjunctivitis
15. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication
16. Protective effect of interferon on infections with hand, foot and mouth disease virus in newborn mice
17. The 2-5A system in control and interferon-treated K/BALB cells infected with encephalomyocarditis virus
18. Regulation of a double-stranded RNA modification activity in human cells
19. Interferon action: Binding of viral RNA to the 40 kilodalton 2', 5'-oligoadenylate synthetase in interferon-treated HeLa cells infected with the encephalomyocarditis virus
20. Accumulation of 2',5'-oligoadenylates in encephalomyocarditis virus-infected mice
21. Intranasal interferon alpha-2 for prevention of rhinovirus infection and illness
22. Intranasal interferon-α2 treatment of experimental rhinoviral colds
23. Inhibition of respiratory virus infection by locally applied interferon
24. Prevention of natural colds by contact prophylaxis with intranasal alpha-2-interferon
25. Efficacy and tolerance of intranasal applied recombinant leukocyte A interferon in normal volunteers
26. Three-dimensional structure of poliovirus at 2.9A resolution
27. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids
28. Rhodamine: A selective inhibitor of the multiplication of echovirus 12
29. Antiviral agents against picornaviruses
30. Antipicornavirus flavone Ro 09-0179
31. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RM1-15,731, 4',6-dichloroflavan, and enviroxime
32. In vitro and in vivo antipicornavirus activity of some phenoxypyridine-carbonitriles
33. Antipicornavirus activity of some daryl methanes and aralkylamino-pyridines
34. Preliminary studies of the mode of action of arildone, a novel antiviral agent
35. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug
36. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity
37. SCH-38057: A picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating
38. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activity against human rhinovirus type 14
39. Inhibition of poliovirus uncoating by disoxaril (WIN 51711)
40. Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids
41. Comparison of arildone and 3-methylquercetin as stabilizers of poliovirus
42. Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults
43. In vitro activity of VP 63843 against field isolates of non-polio enteroviruses
44. Activity of pleconaril against enteroviruses
45. A model for compounds active against human rhinovirus-14 based on X-ray crystallography data
46. [(Biaryloxy)alkyl] isoxazoles: Picornavirus inhibitors
47. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism
48. Antiviral therapy for enteroviral infections
49. Enterovirus infections: Diagnosis and treatment
50. Oral efficacy of VP 63843 in coxsackievirus A21 infected volunteers
51. Oral pleconaril reduces the duration and severity of enteroviral meningitis in children
52. Pleconaril is effective for enteroviral meningitis in adolescents and adults: A randomized placebo-controlled multicenter trial
53. Pleconaril treatment of chronic enteroviral central nervous system infections in children with agammaglobulinemia
54. Pleconaril therapy of potentially life-threatening enterovirus infections
55. Pleconaril treatment of vaccine-acquired poliovirus
56. Efficacy of pleconaril in the treatment of aseptic meningitis in adults
57. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound
58. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants
59. Escape mutant analysis of a drug-binding site can be used to map functions in the rhinovirus capsid
60. Pathogenesis for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410